Immunotherapy Archives

News and Trends 28 Jul 2021

Microbiome Medicines Could Power Up CAR-T Cell Therapies

The microbiome could pave new cancer immunotherapy inroads for European biotechs, bolstered by preclinical findings that gut bacteria metabolites may help CAR-T cell therapies penetrate and kill solid tumors. A recent study conducted by researchers at Philipps-University Marburg, University Hospital Würzburg, and the Leeds-based company 4D Pharma showed that metabolites produced by the gut bacteria […]

July 28, 2021 - 5 minutesmins - By Mark Zipkin

News and Trends 26 Jul 2021

Europe’s TCR Therapy Scene Gains Traction with €40M Series B

Swedish firm Anocca’s fundraising is the first major venture capital round to go to a European TCR therapy developer this year; another sign that the technology is gaining momentum. Last year was a busy one for companies developing cell therapies for cancer based on engineering T-cell receptors (TCRs), known as TCR or TCR-T cell therapies. […]

July 26, 2021 - 5 minutesmins - By Jonathan Smith

News and Trends 8 Jul 2021

The Top European Biotech Funding Rounds in June

While oncology and psychedelics dominated European biotech’s biggest funding rounds last month, startup seed financing focused more on gene therapy and drug discovery. Last month saw some momentous events for Europe’s biotech heavyweights. GSK paid an impressive €524M ($625M) upfront to co-develop an immuno-oncology candidate with iTeos Therapeutics in Belgium. Meanwhile, the German antibody drug […]

July 8, 2021 - 5 minutesmins - By Jonathan Smith

News and Trends 30 Jun 2021

GSK Raises Eyebrows in Checkpoint Inhibitor Megadeal with iTeos

Analysts are abuzz over GSK’s co-development deal with immuno-oncology specialist iTeos Therapeutics earlier this month, wondering if it overpaid for the Belgian company’s next-generation checkpoint inhibitor. GSK’s oncology deal with iTeos earlier this month centered on an antibody drug that blocks an immune checkpoint called TIGIT. The candidate is currently in phase I testing for […]

June 30, 2021 - 5 minutesmins - By Victor Kotsev

dna sequencing covid 19 vaccine funding european biotech investment

News and Trends 10 Jun 2021

The Top European Biotech Investment Rounds in May

Last month saw huge biotech investment rounds dedicated to Covid-19 vaccines in Europe, including IPOs by Valneva and Vaccitech. However, a €227M (£195M) private round by the DNA sequencing giant Oxford Nanopore Technologies made the biggest splash. Last month was a difficult one for a number of public biotech companies. Biotech stock indices proved volatile […]

June 10, 2021 - 4 minutesmins - By Jonathan Smith

Interview 26 May 2021

Immuno-Oncology: From Science Fiction to the Mainstream

In just a couple of decades, immuno-oncology has taken center stage in the biotechnology industry. We discuss the evolution of the field with experts who have been in it from the very beginning. While immuno-oncology is one of the hottest areas of medicine at the moment, that wasn’t the case 20 years ago. The idea […]

May 26, 2021 - 7 minutesmins - By Clara Rodríguez Fernández

medical cancer checkpoint inhibitor immunotherapy

News and Trends 29 Apr 2021

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors

Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel immune checkpoint target in nearly a decade. This could herald the next generation of checkpoint inhibitors against cancer. Last month, the antibody drug relatlimab, developed by Bristol Myers Squibb, increased the progression-free survival of melanoma patients in phase III. These […]

April 29, 2021 - 5 minutesmins - By Mark Zipkin

neoantigen immuno oncology cancer therapy achilles therapeutics

News and Trends 15 Apr 2021

Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens

The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month may have been a long-delayed starter pistol for investments into neoantigen-based therapies, a family of personalized cancer immunotherapies that target proteins unique to an individual’s tumor. Neoantigen-focused companies have closed smaller initial public offerings (IPOs) in the past. Two major […]

April 15, 2021 - 5 minutesmins - By Mark Zipkin

VC finance stock funds ipo gamma delta t cell lava therapeutics

News and Trends 31 Mar 2021

Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells

The Dutch biotech startup Lava Therapeutics launched onto the Nasdaq stock market last week with an €85.6M ($100.5M) IPO. This is a sign of mounting investor interest in cancer treatments based on immune cells known as gamma delta T cells. The proceeds of the IPO will be used to drive the development of the company’s […]

March 31, 2021 - 5 minutesmins - By Anita Chakraverty

News and Trends 25 Mar 2021

Covid-19 Vaccine Approvals Bring Hope and Challenges for Adenoviral Technology

The rise of adenoviral Covid-19 vaccines highlights the potential of companies using similar technology in other fields like cancer or gene therapy. However, complex challenges remain, such as circumventing immunity to adenoviral treatments. Earlier this month, Johnson & Johnson’s candidate became the first single-shot Covid-19 vaccine to get the EMA green light. The vaccine is […]

March 25, 2021 - 6 minutesmins - By Victor Kotsev

In Depth 22 Mar 2021

Can Immunotherapy Offer Hope for Parkinson’s Sufferers?

Despite decades of research, effective treatments for Parkinson’s disease are proving elusive. Could immunotherapy finally provide a solution? More than seven million people worldwide are currently living with Parkinson’s disease, an incurable neurodegenerative disorder. Current treatment options are limited as they only attempt to mask the symptoms rather than address the cause. But there is […]

March 22, 2021 - 5 minutesmins - By David Cox

News and Trends 26 Jan 2021

Oxford’s Covid-19 Vaccine Blazes Trail for Oncolytic Virus Firms

Since the debut of Imlygic in 2015, no other oncolytic virus cancer therapies have been approved by the FDA and EMA. However, we’re seeing the first signs that the Covid-19 pandemic may help the field get out of the rut. Earlier this month, the Oxford-based firm Theolytics raised €5.6M in a Series A round. This […]

January 26, 2021 - 7 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Microbiome Medicines Could Power Up CAR-T Cell Therapies

Europe’s TCR Therapy Scene Gains Traction with €40M Series B

The Top European Biotech Funding Rounds in June

GSK Raises Eyebrows in Checkpoint Inhibitor Megadeal with iTeos

The Top European Biotech Investment Rounds in May

Immuno-Oncology: From Science Fiction to the Mainstream

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors

Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens

Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells

Covid-19 Vaccine Approvals Bring Hope and Challenges for Adenoviral Technology

Can Immunotherapy Offer Hope for Parkinson’s Sufferers?

Oxford’s Covid-19 Vaccine Blazes Trail for Oncolytic Virus Firms

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!